CNS Pharma Reports Executive/Director Changes, Comp Arrangements
Ticker: CNSP · Form: 8-K · Filed: Jan 23, 2024 · CIK: 1729427
| Field | Detail |
|---|---|
| Company | Cns Pharmaceuticals, Inc. (CNSP) |
| Form Type | 8-K |
| Filed Date | Jan 23, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: executive-changes, compensation, governance
TL;DR
**CNS Pharma just filed an 8-K about leadership and pay changes, keep an eye on it.**
AI Summary
CNS Pharmaceuticals, Inc. filed an 8-K on January 23, 2024, reporting an event that occurred on January 17, 2024. The filing indicates changes related to the 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.' This matters to investors because changes in leadership or executive compensation can signal shifts in company strategy, financial health, or governance, potentially impacting future stock performance.
Why It Matters
Changes in executive leadership and compensation can significantly influence a company's direction and stability, directly affecting investor confidence and stock valuation.
Risk Assessment
Risk Level: medium — Changes in executive leadership can introduce uncertainty regarding future company strategy and performance, posing a medium risk to investors.
Analyst Insight
Investors should monitor subsequent filings or press releases from CNS Pharmaceuticals, Inc. for specific details regarding the personnel changes and compensation arrangements to understand their potential impact on the company's future operations and financial health.
Key Players & Entities
- CNS Pharmaceuticals, Inc. (company) — the registrant filing the 8-K
- January 17, 2024 (date) — date of the earliest event reported
- January 23, 2024 (date) — date the 8-K was filed
FAQ
What was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on January 17, 2024.
What specific items are covered under Item 5.02 of this 8-K filing?
Item 5.02 covers 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers'.
What is the full business address of CNS Pharmaceuticals, Inc. as stated in the filing?
The business address is 2100 West Loop South, Suite 900, Houston, Texas 77027.
What is the telephone number for CNS Pharmaceuticals, Inc.?
The telephone number for CNS Pharmaceuticals, Inc. is (800) 946-9185.
What is the Commission File Number for CNS Pharmaceuticals, Inc.?
The Commission File Number for CNS Pharmaceuticals, Inc. is 001-39126.
Filing Stats: 472 words · 2 min read · ~2 pages · Grade level 11.1 · Accepted 2024-01-23 16:01:11
Key Financial Figures
- $0.001 — ch registered Common stock, par value $0.001 per share CNSP The NASDAQ Stock Marke
Filing Documents
- cns_8k.htm (8-K) — 28KB
- 0001683168-24-000393.txt ( ) — 198KB
- cnsp-20240117.xsd (EX-101.SCH) — 3KB
- cnsp-20240117_lab.xml (EX-101.LAB) — 33KB
- cnsp-20240117_pre.xml (EX-101.PRE) — 22KB
- cns_8k_htm.xml (XML) — 3KB
02 Departure of Directors or Certain
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On January 17, 2024, the Board of Directors of CNS Pharmaceuticals, Inc. (the "Company") agreed to appoint Amy Mahery as an independent member of the Company's Board of Directors effective upon the completion of the Company's financing. Ms. Mahery has not been appointed to any Board committees at this time. Upon Ms. Mahery's appointment, she will participate in the Company's standard compensation program for non-employee directors, which was filed as Exhibit 10.1 to the Company's Form 10-Q for the quarter ended June 30, 2022 and is incorporated herein by reference. 2 Signature Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CNS Pharmaceuticals, Inc. By: /s/ Chris Downs Chris Downs Chief Financial Officer Dated: January 23, 2024 3